[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642597":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"CHA University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"autologous tumor-infiltrating lymphocytes(TILs) for the treatment",null,[12],"Other: autologous tumor-infiltrating lymphocytes",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"autologous tumor-infiltrating lymphocytes","Autologous tumor-infiltrating lymphocytes are cultured from tumor cells collected from the subject and administered as a single intravenous injection to the subject.",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Yong Wha Moon","CONTACT","82-31-780-3436","ymoon@cha.ac.kr",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":10,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Bundang CHA Medical Center","RECRUITING","Gyeonggi-do","Bundang-gu","13520","South Korea",{"type":33,"coordinates":34},"Point",[35,36],126.76917,37.58944,{"lat":36,"lon":35},[39],{"name":40,"role":21,"phone":41,"phoneExt":10,"email":42},"Miyoung Kim","82-31-780-5306","a210647@chamc.co.kr",{"type":44,"investigatorFullName":20,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Professor","100642597","to-evaluate-the-safety-of-autologous-tumor-infiltrating-lymphocytestils-for-the-treatment-of-recurrent-ovarian-cancer-100642597",false,"NCT07651124","To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer","A Clinical Trial to Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Recurrent ovarian cancer\n* There is a cancerous lesion that can be removed by biopsy or surgery.\n\nExclusion Criteria:\n\n* Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy\n* Patient deemed unsuitable by the principal investigator","FEMALE","20 Years",{"count":56,"type":57},6,"ESTIMATED","INTERVENTIONAL",[60],"NA","The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer.\n\nParticipants undergo the following process:\n\nThere must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject.\n\nThese are processed into human cells for administration and injected into the subject.",[63],"Recurrent Ovarian Cancer","2026-06-15",{"date":66,"type":67},"2026-06-16","ACTUAL",{"date":69,"type":67},"2025-04-01",{"date":71,"type":57},"2027-06-30",{"name":20,"class":6},1]